

Urinary Protein Creatinine Ratio in PHN Rat Model
****
UPCR (mg/mg)
Mean ± SEM
50
40
30
20
10
0
4
7
11
14
Day
*
***
****
¥¥
¥¥
¥¥
Vehicle Control
Anti-Fx1A
Anti-Fx1A + Cmpd A (30 mg/kg/day, PO)
* vs. control
¥ vs. Cmpd A
2 Way ANOVA, Tukey post-hoc

FIG. 1



NGAL excretion in Urine at Day 14 from
PHN Rat Study and with Cmpd A
Treatment (30 mg/kg/day PO)
NGAL:UCre (ng/mg)
1500
1000
500
0
***
***
× 3.3
68%
Control
Anti-Fx1A (3 ml/kg)
Anti-Fx1A + Cmpd A
(30 mg/kg/day, PO)

FIG. 2A



Complement Factor Ba Fragment Quantification
in PHN Rat Model
(treatment with Cmpd A at 30 mg/kg/day PO)
Ba:UCre (ug/mg)
Mean ± SEM
8
6
4
2
0
Control
Anti-Fx1A (3 ml/kg)
Cmpd A
↓ 84%
****
****
ns
Day4
Day7
Day14

FIG. 2B



Full Length Complement Factor B Elevation in Urine in PHN Rat Model with Cmpd A (30 mg/kg/day, PO)
FB:UCre (ug/mg)
Mean ± SEM
10
8
6
4
2
0
Control
Anti-Fx1A (3 ml/kg)
Cmpd A
↑x4.8
***
ns
Day4
Day7
Day14

FIG. 3A



NGAL excretion in Urine at Day 14 from PHN Rat Study and with Cmpd A Treatment (30 mg/kg/day PO)
NGAL:UCre (ng/mg)
1500
1000
500
0
***
***
x 3.3
68%
Control
Anti-Fx1A (3 ml/kg)
Anti-Fx1A + Cmpd A (30 mg/kg/day, PO)

FIG. 3B



Urinary KIM1 execretion in PHN Rat Model with Cmpd A Treatment (30 mg/kg/day PO)
x 7
88%
***
***
15
10
5
0
KIM1:UCre (ng/mg)
Control
Anti-Fx1A (3 ml/kg)
Anti-Fx1A + Cmpd A

FIG. 4